# Bregua

> Bregua is a VC fund backing Biotechnology, Therapeutics and Biopharma. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 8
- Last investment: Nov 2024
- Lead investor: 13%
- Last updated: Aug 2026

Bregua is a VC fund focused on Biotechnology and Therapeutics. Bregua Corporation

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Therapeutics | 4 | 50% |
| Biopharma | 2 | 25% |
| Health Care | 2 | 25% |
| Real Time | 1 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 38% |
| Series B | 2 | 25% |
| Seed | 1 | 13% |
| Series C | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 63% |
| Germany | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Valora Therapeutics | Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies . | $30M | Seed | Nov 20, 2024 |  |
| Enlaza Therapeutics | Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M | Series A | Apr 30, 2024 |  |
| Janux Therapeutics | Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. | $125M | Series B | Apr 20, 2021 |  |
| Fortis Therapeutics | Fortis Therapeutics is immuno-oncology biotech focused on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. | $40M | Series A | Mar 29, 2021 |  |
| Janux Therapeutics | Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. | $56M | Series A | Mar 03, 2021 |  |
| Acousia Therapeutics | Acousia Therapeutics GmbH is a privately held biotech company based in Tübingen, Germany. Acousia has experience and expertise in identifying and developing small molecule drug candidates for the treatment of hearing loss.Sensory hair cells are the key cells for hearing in the inner ear. Acousia`s approach will help to replace lost hair cells bycellular regeneration originating from supporting cells.ASpherecousia is developing drugs for local application, which will restore hearing in patients who have lost their hearing ability induced by various reasons, e.g. noise trauma, treatment with ototoxic drugs or sudden deafness. In addition, these therapies will have the potential to treat the age-related decrease in hearing capacity. | $11M | Series B | May 14, 2018 |  |
| Fortis Therapeutics | Fortis Therapeutics is immuno-oncology biotech focused on developing new antibody-drug conjugate therapies against CD46 for the treatment of late-stage multiple myeloma and late-stage prostate cancer and other indications. | $18M | Series A | Sep 27, 2016 |  |
| Avelas Biosciences | At Avelas Biosciences, their mission is to advance a new standard-of-care in cancer surgery by providing a real time luminous map for oncologic surgeons, leading to improved surgical results and better outcome for patients. | $20M | Series C | Aug 18, 2016 |  |

8 of 8 investments shown.

## Co-investors
- [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures) — VC Fund, 6 deals together
- [Correlation Ventures](https://shizune.co/investors/profile/correlation-ventures) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [OUP (Osage University Partners)](https://shizune.co/investors/profile/osage-university-partners) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Bregua invest in?

Bregua invests primarily in Biotechnology, Therapeutics and Biopharma startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bregua last invest?

The most recent investment recorded for Bregua closed in Nov 2024. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co